Blog
Is Retatrutide Legal to Buy? What Applies to Research Orders in 2026
Retatrutide isn’t approved anywhere in the world, yet it takes a few clicks to find it for sale: small vials of white powder from US research suppliers, priced by the milligram and delivered in days. So the question usually comes up right before a first order. Is any of this allowed?
The news of 2026 made it louder. In August, Lilly filed six lawsuits over retatrutide sales, and the FDA sent another round of letters to online peptide sellers the same month. Read closely, every one of those actions named a business that sold retatrutide. None named a person who bought it.
Simms Research sells Retatrutide (GLP-3) as a research compound to buyers 21 and over, with the lab report for the current batch posted before anyone orders, and ships it from Florida.
Is retatrutide legal in the US?
As a research compound, yes: US suppliers sell it openly, and buyers order it for research with no prescription involved. As a medicine, it doesn’t exist yet.
No regulator has approved retatrutide for any use. Lilly plans to file it with the FDA between January and March 2027, and until a decision comes back no doctor can prescribe it and no pharmacy can fill it. When Will Retatrutide Be FDA Approved? lays out the review clock from filing to launch.
That leaves one form on the market, the freeze-dried powder sold for laboratory research. It is the same molecule Lilly is testing, LY3437943, a single peptide that acts on three hormone receptors; What Is Retatrutide? covers what it does and what the trials measured. Pharmacies, compounders and clinics are a separate story, and Retatrutide Near Me takes them one at a time.

Is it legal to buy retatrutide online?
Research buyers do it every day. Online is how retatrutide is bought in the US: research suppliers ship it as a freeze-dried powder, vial by vial, by UPS and FedEx to all 50 states, and ask for no prescription, because what they sell is a research compound rather than a drug product.
What applies to the buyer is settled at the order. At Simms Research the buyer has to be 21 or older and confirms the order is for research and laboratory use, not for people or animals, and every product in the catalog is sold on those terms.
Retatrutide research use only: what it means
It means the vial is sold as a material for laboratory work, not as a medicine. A research compound comes with no approved use, no prescribing label and no dose on the box; what it comes with is a certificate showing what’s in it. That label also separates the supplier from a pharmacy: Simms Research is neither a compounding pharmacy nor an outsourcing facility, and it doesn’t prepare anything for a named patient.

What the FDA has done about retatrutide and GLP-1 drugs
It has worked on three fronts since late 2024: pharmacy compounding, sales under a research label and imported ingredients. Lilly joined in 2026 with its own lawsuits. Here is each step, and who it was aimed at:
| When | Who acted | Aimed at | What it did |
|---|---|---|---|
| December 2024 | FDA | Online sellers of research-labeled GLP-1s | Warning letters, retatrutide among the compounds |
| February to May 2025 | FDA | Compounding pharmacies | Ended shortage-era copies of tirzepatide and semaglutide |
| September 2025 | FDA | Imported GLP-1 ingredients | Import alert on makers it hasn’t vetted |
| March to June 2026 | FDA | Telehealth companies | 55 warning letters over compounded GLP-1 ads |
| August 12, 2026 | Lilly | Four research sellers, a med spa, a pharmacy | Six lawsuits to stop their retatrutide sales |
| August 24, 2026 | FDA | Online peptide sellers | Five warning letters, retatrutide among the compounds |
Compounding is closed to retatrutide altogether. The FDA has said plainly that it can’t be used in compounding, since it isn’t part of any approved drug, and the HHS notice that opened six other peptides to pharmacies on October 28, 2026 left it out; the RFK peptides list has the six.
Tirzepatide and semaglutide ran on a different track. Pharmacies were allowed to copy them while Zepbound and Wegovy were in shortage, and that window shut once the FDA declared both shortages over, tirzepatide’s in December 2024 and semaglutide’s in February 2025. The 2026 telehealth letters were about how those compounded versions were advertised.
Retatrutide lawsuit update
Two sets of court cases carry retatrutide’s name. One is Lilly against six sellers; the other is Lilly against the FDA. Neither involves a buyer.
Lilly’s lawsuits against retatrutide sellers
On August 12, 2026, Lilly filed six lawsuits in federal courts in Texas and California. The defendants are four sellers that labeled their retatrutide for research use, one med spa and one compounding pharmacy. Lilly asks the courts for permanent orders barring each company from selling anything that contains, or claims to contain, retatrutide, plus the profits made from it.
Lilly said at the same time that it had flagged more than 14,000 listings offering retatrutide across 100 countries to the platforms carrying them. As of mid-November 2026, no ruling in any of the six cases had been reported.
Lilly vs the FDA over retatrutide
This one is about Lilly’s years of exclusive sales after approval, not about who can sell it now. In March 2024 the FDA classed retatrutide as a drug rather than a biologic, counting fewer than 40 of its amino acids toward the line that makes a protein; Lilly counts 41 and sued in September 2024. The label matters because a biologic gets 12 years before copies can follow and a drug gets 5, and a biologic can never be compounded.
A federal court in Indiana split the question in September 2025, and Lilly’s appeal was argued on September 24, 2026, with no decision yet. Lilly plans to file in the first quarter of 2027 either way.
Is it illegal to buy retatrutide in the US?
Every step in the table was aimed at a business: research sellers, telehealth companies, pharmacies, a med spa and overseas ingredient makers. The FDA’s letters and Lilly’s suits went to the companies doing the selling, and not one was addressed to a customer.
Using it is a separate question from buying it. Research retatrutide is sold for laboratory work, and that is the use a buyer signs up to. Taking retatrutide as a medicine before approval runs through a Lilly trial or Lilly’s expanded access program, and retatrutide early access sets out who qualifies.
Is retatrutide legal in California, Texas and Florida?
Its status is the same in every state, since drug approval is federal. Research orders go out the same way to all 50, California, Texas and Florida included.

How research buyers order retatrutide
From a US supplier that publishes the batch’s lab report and ships from inside the country, so the vial never passes through customs. Simms Research’s Retatrutide (GLP-3) comes in 10, 20, 30 and 60mg vials, priced at $84, $129, $159 and $259.
The report is public before checkout. The July 16, 2026 batch measured 10.68mg in a vial labeled 10mg and came back 99.611% pure across three tested vials, with the molecule’s identity confirmed by mass spectrometry, and its endotoxin, heavy-metal and microbial screens all passed. The certificate is posted with the retatrutide lab results; the guide How to Read a Peptide COA walks through every field on it.
Orders in by 5PM Eastern leave Florida that afternoon, and later ones go out the next business day, by UPS Standard in three to five business days or by FedEx 2-Day, free over $200. If a box goes missing in transit, disappears after the delivery scan or turns up damaged, the Free Delivery Guarantee replaces it, or refunds it when no replacement is on hand.
Is retatrutide legal to buy?
For research, yes. Retatrutide is sold in the US as a research compound, ordered online without a prescription by adults who agree to research use, and shipped to every state. It isn’t an approved medicine and it can’t be compounded, and the letters and lawsuits of 2026 were aimed at businesses, not the people who bought from them.
A prescription version comes only after the FDA rules on Lilly’s 2027 application. Until then, Simms Research’s Retatrutide (GLP-3) leaves Florida with its lab report open to read, and the rest of the catalog is in the shop.
Frequently asked questions
Is retatrutide legal to possess?
It isn’t a controlled substance. Retatrutide sits on no DEA schedule, the same as semaglutide and tirzepatide, unlike testosterone and other anabolic steroids.
Is retatrutide legal yet as a prescription drug?
Not yet. Lilly files in the first quarter of 2027, and on the FDA’s usual clock a decision lands in early 2028, or in the autumn of 2027 with a priority review.
Is retatrutide legal in the UK, Canada or Australia?
None of the three has approved it, and each sets its own rules for unapproved compounds arriving from abroad, separate from the US research market.
Is Simms Research legit?
It’s a US supplier shipping from Florida, with the retatrutide certificate public before anyone pays and the delivery guarantee on every order. Support picks up on 855-592-8507 and answers support@simmsresearch.com on weekdays between 9AM and 5PM Eastern, usually within a business day.
Does this page carry a coupon code or affiliate link?
No. Every price here is the regular one, and no link on the page pays anyone.